Skip to main content
Research

Publications: Dr Michelle Lockley

Cohen PA, Powell A, Böhm S, Gilks CB, Stewart CJR, Meniawy TM, Bulsara M, Avril S et al. ( 2021 ) . Corrigendum to “Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data” Gynecol. Oncol. 154 (2019) 441–448 (Gynecologic Oncology (2019) 154(2) (441–448), (S0090825819311813), (10.1016/j.ygyno.2019.04.679)) . Gynecologic Oncology
Shamash J, Ansell W, Alifrangis C, Thomas B, Wilson P, Stoneham S, Mazhar D, Warren A et al. ( 2021 ) . The impact of a supranetwork multidisciplinary team (SMDT) on decision-making in testicular cancers: a 10-year overview of the Anglian Germ Cell Cancer Collaborative Group (AGCCCG) . Br J Cancer vol. 124 , ( 2 ) 368 - 374 .
Morgan RD, McNeish IA, Cook AD, James EC, Lord R, Dark G, Glasspool RM, Krell J et al. ( 2020 ) . Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial . Lancet Oncol
Alifrangis C, Sharma A, Chowdhury S, Duncan S, Milic M, Gogbashian A, Agarwal S, Sahdev A et al. ( 2020 ) . Single-agent carboplatin AUC10 in metastatic seminoma: A multi-centre UK study of 216 patients . Eur J Cancer
Cohen PA, Powell A, Böhm S, Gilks CB, Stewart CJR, Meniawy TM, Bulsara M, Avril S et al. ( 2020 ) . Corrigendum to “Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data” [Gynecol. Oncol. 154 (2019) 441–448] (Gynecologic Oncology (2019) 154(2) (441–448), (S0090825819311813), (10.1016/j.ygyno.2019.04.679)) . Gynecologic Oncology vol. 157 , ( 2 ) 558 - 559 .
Berney DM, Shamash J, Stoneham S, Lockley M ( 2020 ) . Response to: A multicentre retrospective cohort study of ovarian germ cell tumours: Evidence for chemotherapy de-escalation and alignment of paediatric and adult practice . Eur J Cancer vol. 130 , 267 - 268 .
Casey L, Powell A, Bohm S, Manchanda R, Lockley M, Kobel M, Singh N ( 2020 ) . Role of Ki67 Proliferation Index and CD8 Tumour-Infitrating Lymphocyte Counts in Predicting Outcome in High-Grade Serous Tubo-Ovarian Carcinoma (HGSC) Showing No/Partial Response to Neoadjuvant Chemotherapy . MODERN PATHOLOGY . vol. 33 , 1024 - 1024 .
McLeavy L, Rahman B, Kristeleit R, Ledermann J, Lockley M, McCormack M, Mould T, Side L et al. ( 2020 ) . Mainstreamed genetic testing in ovarian cancer: patient experience of the testing process . Int J Gynecol Cancer vol. 30 , ( 2 ) 221 - 226 .
Berney DM, Stoneham S, Arora R, Shamash J, Lockley M ( 2020 ) . Ovarian germ cell tumour classification: views from the testis . Histopathology vol. 76 , ( 1 ) 25 - 36 .
Wood GE, Lockley M, Kermorgant S ( 2019 ) . 68PC-met mediates invasion and chemotherapy resistance in high grade serous ovarian cancer . Annals of Oncology . vol. 30 ,
Macintyre G, Goranova TE, De Silva D, Ennis D, Piskorz AM, Eldridge M, Sie D, Lewsley L-A et al. ( 2019 ) . COPY-NUMBER SIGNATURES AND MUTATIONAL PROCESSES IN HIGH GRADE SEROUS OVARIAN CARCINOMA . CLINICAL CANCER RESEARCH . vol. 25 , 64 - 64 .
Hockings H, Wood G, Lockley M ( 2019 ) . EP870 Bevacizumab facilitates surgery in previously inoperable patients with low-grade serous ovarian cancer: a case series . International Journal of Gynecological Cancer . vol. 29 ,
Hockings HA, Mossner M, Lakatos E, Graham T, Lockley M ( 2019 ) . Low pass whole genome sequencing can be used to calculate the relative proportion of chemotherapy resistant disease in high grade serous ovarian cancer . Annals of Oncology . vol. 30 ,
Heath O ( 2019 ) . The effects of neo-adjuvant chemotherapy on myeloid cells in high-grade serous ovarian cancer metastases .
Newton C, Murali K, Ahmad A, Hockings H, Graham R, Liberale V, Sarker S-J, Lockley M ( 2019 ) . GCT-30 Surgical management of ovarian germ cell tumours . European Urology Supplements vol. 18 , ( 4 )
Shamash J, Ansell W, Alifrangis C, Sahdev A, Thomas B, Wilson P, Mazhar D, Warren A et al. ( 2019 ) . GCT-84 The impact of a supranetwork-multidisciplinary team (SMDT) on decision making in testicular cancers: A ten-year overview of the Anglian Germ Cell Cancer Collaborative Group (AGCCCG) . European Urology Supplements vol. 18 , ( 4 )
Heath OM, Maniati E, Belato C, Gopinathan G, Lecker L, Lakhani A, Pegrum C, McDermott J et al. ( 2019 ) . Abstract 1103: The effects of neo-adjuvant chemotherapy on myeloid cells in high-grade serous ovarian cancer metastases . 1103 - 1103 .
Saxena J, Nicolini F, Lockley M ( 2019 ) . Abstract 3801: Reversing chemoresistance in high grade serous ovarian cancer . 3801 - 3801 .
Cohen PA, Powell A, Böhm S, Gilks CB, Stewart CJR, Meniawy TM, Bulsara M, Avril S et al. ( 2019 ) . Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data . Gynecologic Oncology
Newton C, Murali K, Ahmad A, Hockings H, Graham R, Liberale V, Sarker SJ, Ledermann J et al. ( 2019 ) . A multicentre retrospective cohort study of ovarian germ cell tumours: Evidence for chemotherapy de-escalation and alignment of paediatric and adult practice . European Journal of Cancer vol. 113 , 19 - 27 .
Goranova T, Ennis D, Piskorz AM, Macintyre G, Lewsley LA, Stobo J, Wilson C, Kay D et al. ( 2019 ) . Correction: Safety and utility of image-guided research biopsies in relapsed high-grade serous ovarian carcinoma—experience of the BriTROC consortium (British Journal of Cancer, (2017), 116, 10, (1294-1301), 10.1038/bjc.2017.86) . British Journal of Cancer vol. 120 , ( 8 )
Rahman B, Lanceley A, Kristeleit RS, Ledermann JA, Lockley M, McCormack M, Mould T, Side L ( 2019 ) . Mainstreamed genetic testing for women with ovarian cancer: first-year experience . J Med Genet vol. 56 , ( 3 ) 195 - 198 .
Lockley M, Stoneham SJ, Olson TA ( 2019 ) . Ovarian cancer in adolescents and young adults . Pediatr Blood Cancer vol. 66 , ( 3 )
Böhm S, Le N, Lockley M, Brockbank E, Faruqi A, Said I, Jeyarajah A, Wuntakal R et al. ( 2019 ) . Histopathologic response to neoadjuvant chemotherapy as a prognostic biomarker in tubo-ovarian high-grade serous carcinoma: updated Chemotherapy Response Score (CRS) results . Int J Gynecol Cancer
Lockley M, Newton C, Murali K, Ahmed A, Hockings H, Berney D, Shamash J, Banerjee S et al. ( 2018 ) . A multicentre analysis of malignant ovarian germ cell tumours: rationale for alignment of paediatric and adult practice and for chemotherapy de-escalation in specific subtypes . INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER . vol. 28 , 42 - 43 .
Wood GE, Heuss SF, Osagie I, Lockley M, Kermorgant S ( 2018 ) . c-Met signalling and endocytosis in clear cell ovarian cancer . INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER . vol. 28 , 95 - 95 .
Macintyre G, Goranova TE, De Silva D, Ennis D, Piskorz AM, Eldridge M, Sie D, Lewsley LA et al. ( 2018 ) . Copy number signatures and mutational processes in ovarian carcinoma . Nature Genetics vol. 50 , ( 9 ) 1262 - 1270 .
Hoare JI, Saxena J, Hockings H, McDermott J, Browne A, Lockley M ( 2018 ) . Abstract A54: Generation and characterization of a novel panel of platinum-resistant HGSOC models . a54 - a54 .
Walton J, Farquharson M, Mason S, Blagih J, Ennis D, Leung E, Dowson S, Athineos D et al. ( 2018 ) . Abstract PR14: CRISPR/Cas9-mediated Trp53, Brca1, Brca2, Pten, and Nf1 knockout to generate improved murine models of ovarian high-grade serous carcinoma . pr14 - pr14 .
Walton J, Farquharson M, Mason S, Blagih J, Ennis D, Leung E, Dowson S, Athineos D et al. ( 2018 ) . CRISPR/Cas9-mediated Trp53, Brca1, Brca2, Pten, and Nf1 knockout to generate improved murine models of ovarian high-grade serous carcinoma . CLINICAL CANCER RESEARCH . vol. 24 , 36 - 37 .
Hoare JI, Saxena J, Hockings H, McDermott J, Browne A, Lockley M ( 2018 ) . Generation and characterization of a novel panel of platinum-resistant HGSOC models . CLINICAL CANCER RESEARCH . vol. 24 , 68 - 68 .
Devlin M-J, Chandrasekaran D, Singh N, Ledermann JA, Lockley M, McCormack M, Wilkinson N, Miller R et al. ( 2018 ) . Clear cell ovarian cancer (CCOC): 115 patient (pt) series showing access to experimental therapy may improve response rates in recurrent disease . Journal of Clinical Oncology vol. 36 , ( 15_suppl ) 5581 - 5581 .
Fearon AE, Carter EP, Clayton NS, Wilkes EH, Baker AM, Kapitonova E, Bakhouche BA, Tanner Y et al. ( 2018 ) . PHLDA1 Mediates Drug Resistance in Receptor Tyrosine Kinase-Driven Cancer . Cell Reports vol. 22 , ( 9 ) 2469 - 2481 .
Pearce OMT, Delaine-Smith R, Maniati E, Nichols S, Wang J, Böhm S, Rajeeve V, Ullah D et al. ( 2017 ) . Deconstruction of a metastatic tumor microenvironment reveals a common matrix response in human cancers . Cancer Discov
Casey L, Köbel M, Ganesan R, Tam S, Prasad R, Böhm S, Lockley M, Jeyarajah AJ et al. ( 2017 ) . A comparison of p53 and WT1 immunohistochemical expression patterns in tubo-ovarian high-grade serous carcinoma before and after neoadjuvant chemotherapy . Histopathology vol. 71 , ( 5 ) 736 - 742 .
McDermott JR, Jones R, Lockley M, Balkwill FR ( 2017 ) . The Chemokine CXCL10 is a Potential Regulator of Cancer Stem Cells in High Grade Serous Carcinoma . JOURNAL OF PATHOLOGY . vol. 243 , S15 - S15 .
Walton J, Blagih J, Farquharson M, Ennis D, Leung E, Dowson S, Tookman LA, Orange C et al. ( 2017 ) . Abstract AP24: CRISPR/CAS9–MEDIATED TRP53 , BRCA1 , BRCA2 AND PTEN KNOCKOUT TO GENERATE IMPROVED MURINE MODELS OF OVARIAN HIGH GRADE SEROUS CARCINOMA . ap24 - ap24 .
Glasspool RM, Blagden SP, Lockley M, Paul J, Hopkins C, Thomson F, Brown J, Fernandes R et al. ( 2017 ) . A phase I trial of the oral hedgehog inhibitor taladegib (LY2940680) in combination with weekly paclitaxel in patients with advanced, solid tumours . Journal of Clinical Oncology vol. 35 , ( 15_suppl ) 2594 - 2594 .
Goranova T, Ennis D, Piskorz AM, MacIntyre G, Lewsley LA, Stobo J, Wilson C, Kay D et al. ( 2017 ) . Safety and utility of image-guided research biopsies in relapsed high-grade serous ovarian carcinoma - Experience of the BriTROC consortium . British Journal of Cancer vol. 116 , ( 10 ) 1294 - 1301 .
Ganesan R, Singh N, Casey L, Tam S, Farugi A, Prasad R, Boehm S, Lockley M et al. ( 2017 ) . Immunohistochemical Expression of p53 and WT1 Is Retained Following Chemotherapy in High-Grade Serous Tubo-Ovarian Carcinoma (HGSC) . LABORATORY INVESTIGATION . vol. 97 , 286A - 287A .
La Russa M, Kokka F, Lockley M, Brockbank E ( 2016 ) . Haemorrhagic shock due to spontaneous splenic rupture in a patient subsequently diagnosed with advanced ovarian cancer . J Obstet Gynaecol vol. 37 , ( 2 ) 268 - 270 .
Walton J, Blagih J, Ennis D, Leung E, Dowson S, Farquharson M, Tookman LA, Orange C et al. ( 2016 ) . CRISPR/Cas9-mediated Trp53 and Brca2 knockout to generate improved murine models of ovarian high grade serous carcinoma . Cancer Research
Montfort A, Pearce OMT, Maniati E, Vincent B, Bixby LM, Bo hm S, Dowe T, Wilkes EH et al. ( 2016 ) . A strong B cell response is part of the immune landscape in human high-grade serous ovarian metastases . Clinical Cancer Research
BALKWILL F, Anne Montfort, Oliver Pearce ( 2016 ) . Neoadjuvant chemotherapy modulates the immune microenvironment in metastases of tubo-ovarian high-grade serous carcinoma . Clinical Cancer Research
Walton J, Dowson S, Ennis D, Leung E, Farquharson M, Stevenson D, Blyth K, Strathdee D et al. ( 2016 ) . Abstract B53: CRISPR/Cas9 mediated p53 and BRCA2 knockout to generate improved murine models of high grade serous ovarian cancer . b53 - b53 .
Tookman LA, Browne AK, Connell CM, Bridge G, Ingemarsdotter CK, Dowson S, Shibata A, Lockley M et al. ( 2016 ) . RAD51 and BRCA2 enhance oncolytic adenovirus type 5 activity in ovarian cancer . Molecular Cancer Research vol. 14 , ( 1 ) 44 - 55 .
Montfort A, Boehm S, Dowe T, Topping J, Lockley M, Capasso M, Balkwill F ( 2015 ) . Abstract 455: B cells actively participate to the anti-cancer immune response in high grade serous ovarian cancer metastases . 455 - 455 .
Böhm S, Faruqi A, Said I, Lockley M, Brockbank E, Jeyarajah A, Fitzpatrick A, Ennis D et al. ( 2015 ) . Chemotherapy Response Score: Development and Validation of a System to Quantify Histopathologic Response to Neoadjuvant Chemotherapy in Tubo-Ovarian High-Grade Serous Carcinoma . J Clin Oncol vol. 33 , ( 22 ) 2457 - 2463 .
Browne A, Tookman LA, Ingemarsdotter CK, Bouwman RD, Pirlo K, Wang Y, McNeish IA, Lockley M ( 2015 ) . Pharmacological inhibition of β<inf>3</inf> integrin reduces the inflammatory toxicities caused by oncolytic adenovirus without compromising anticancer activity . Cancer Research vol. 75 , ( 14 ) 2811 - 2821 .
Ingemarsdotter CK, Tookman LA, Browne A, Pirlo K, Cutts R, Chelela C, Khurrum KF, Leung EYL et al. ( 2015 ) . Paclitaxel resistance increases oncolytic adenovirus efficacy via upregulated CAR expression and dysfunctional cell cycle control . Molecular Oncology vol. 9 , ( 4 ) 791 - 805 .
Browne AK, Tookman LA, Ingemarsdotter CK, Bouwman R, Pirlo K, Wang Y, Hodivala-Dilke KM, McNeish IA et al. ( 2014 ) . 106 Beta-3 integrin inhibition reduces inflammatory cytokine release but not anti-cancer activity of oncolytic adenovirus in ovarian cancer . European Journal of Cancer . vol. 50 ,
Spurrell EL, Lockley M ( 2014 ) . Adaptive immunity in cancer immunology and therapeutics . Ecancermedicalscience vol. 8 ,
Leinster DA, Colom B, Whiteford JR, Ennis DP, Lockley M, McNeish IA, Aurrand-Lions M, Chavakis T et al. ( 2013 ) . Endothelial cell junctional adhesion molecule C plays a key role in the development of tumors in a murine model of ovarian cancer . FASEB J vol. 27 , ( 10 ) 4244 - 4253 .
Boehm S, Ennis D, Dowe T, Canosa M, McNeish I, Lockley M, Balkwill F ( 2013 ) . Tumour-associated inflammatory cytokines are reduced following primary platinum-based chemotherapy in plasma of high-grade serous ovarian cancer patients . EUROPEAN JOURNAL OF CANCER . vol. 49 , S736 - S736 .
Rockall AG, Avril NE, Lam R, Mozley PD, Iannone R, Lockley M, Parkinson C, McNeish IA et al. ( 2013 ) . [18F]Fluorodeoxyglucose PET and Volumetric CT analysis are early biomarkers of survival in platinum-sensitive relapsed ovarian cancer - a multicentre trial . EUROPEAN JOURNAL OF CANCER . vol. 49 , S735 - S735 .
Young A-M, Archibald KM, Tookman LA, Pool A, Dudek K, Jones C, Williams SL, Pirlo KJ et al. ( 2012 ) . Failure of translation of human adenovirus mRNA in murine cancer cells can be partially overcome by L4-100K expression in vitro and in vivo . Mol Ther vol. 20 , ( 9 ) 1676 - 1688 .
Leinster DA, Kulbe H, Everitt G, Thompson R, Perretti M, Gavins FNE, Cooper D, Gould D et al. ( 2012 ) . The peritoneal tumour microenvironment of high-grade serous ovarian cancer . J Pathol vol. 227 , ( 2 ) 136 - 145 .
Schultes BC, Lolkema MPJK, Chu CL, Zhou H, Long A, Lockley M, Avery W, Kurtagic E et al. ( 2012 ) . M402, a heparan sulfate mimetic and novel candidate for the treatment of pancreatic cancer . JOURNAL OF CLINICAL ONCOLOGY . vol. 30 ,
Brais RJ, Davies SE, O'Donovan M, Simpson BW, Cook N, Darbonne WC, Chilcott S, Lolkema MP et al. ( 2012 ) . Direct histological processing of EUS biopsies enables rapid molecular biomarker analysis for interventional pancreatic cancer trials . PANCREATOLOGY vol. 12 , ( 1 ) 8 - 15 .
Connell CM, Shibata A, Tookman L, Archibald KM, Flak MB, Pirlo KJ, Lockley M, Wheatley SP et al. ( 2011 ) . Genomic DNA damage and ATR-Chk1 signalling determine adenovirus oncolytic efficacy in ovarian cancer . HUMAN GENE THERAPY vol. 22 , ( 10 ) A113 - A113 .
Connell CM, Shibata A, Tookman LA, Archibald KM, Flak MB, Pirlo KJ, Lockley M, Wheatley SP et al. ( 2011 ) . Genomic DNA damage and ATR-Chk1 signaling determine oncolytic adenoviral efficacy in human ovarian cancer cells . J Clin Invest vol. 121 , ( 4 ) 1283 - 1297 .
Salako MA, Kulbe H, Ingemarsdotter CK, Pirlo KJ, Williams SL, Lockley M, Balkwill FR, McNeish IA ( 2011 ) . Inhibition of the inflammatory cytokine TNF-α increases adenovirus activity in ovarian cancer via modulation of cIAP1/2 expression . Mol Ther vol. 19 , ( 3 ) 490 - 499 .
Flak MB, Connell CM, Chelala C, Archibald K, Salako MA, Pirlo KJ, Lockley M, Wheatley SP et al. ( 2010 ) . p21 Promotes oncolytic adenoviral activity in ovarian cancer and is a potential biomarker . Mol Cancer vol. 9 ,
Salako MA, Connell CM, Shibata A, Graupner V, Lockley M, Balkwill FR, McNeish IA ( 2010 ) . Abstract 591: Host cell DNA damage and inflammation responses determine oncolytic adenovirus efficacy in ovarian cancer . 591 - 591 .
Baird SK, Aerts JL, Eddaoudi A, Lockley M, Lemoine NR, McNeish IA ( 2008 ) . Oncolytic adenoviral mutants induce a novel mode of programmed cell death in ovarian cancer . Oncogene vol. 27 , ( 22 ) 3081 - 3090 .
Baird SK, Ingemarsdotter CK, Eddaoudi A, Lockley M, Lemoine NR, McNeish IA ( 2008 ) . Oncolytic adenoviral mutants define a novel mode of programmed cell death in ovarian cancer . HUMAN GENE THERAPY . vol. 19 , 399 - 399 .
Leyton J, Lockley M, Aerts JL, Baird SK, Aboagye EO, Lemoine NR, McNeish IA ( 2006 ) . Quantifying the activity of adenoviral E1A CR2 deletion mutants using Renilla luciferase bioluminescence and 3 '-deoxy-3 '-[F-18] fluorothymidine positron emission tomography imaging . CANCER RES vol. 66 , ( 18 ) 9178 - 9185 .
Baird SK, Lockley M, Leyton J, Aboagye EO, Lemoine NR, McNeish IA ( 2006 ) . E1A CR2 deletion mutant adenoviral vectors in ovarian cancer: combination with apoptosis inducers and monitoring with [18F] FLT-PET imaging . CANCER RESEARCH . vol. 66 ,
Lockley M, Fernandez M, Wang Y, Li NF, Conroy S, Lemoine N, McNeish I ( 2006 ) . Activity of the adenoviral E1A deletion mutant dl922-947 in ovarian cancer: comparison with E1A wild-type viruses, bioluminescence monitoring, and intraperitoneal delivery in icodextrin . Cancer Res vol. 66 , ( 2 ) 989 - 998 .
McNeish IA, Lopes R, Bell SJ, McKay TR, Fernandez M, Lockley M, Wheatley SP, Lemoine NR ( 2005 ) . Survivin interacts with Smac/DIABLO in ovarian carcinoma cells but is redundant in Smac-mediated apoptosis . Exp Cell Res vol. 302 , ( 1 ) 69 - 82 .
Oakervee HE, Gordon AC, Kaya B, Taussig DC, Lockley M, Barnett MJ, Rohatiner AZS, Lister TA et al. ( 2002 ) . Outcomes of critical illness in patients with haematological malignancy . BLOOD . vol. 100 , 875A - 876A .